Position in RNA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,057,417
New position
Shares Held
602,649
first reported quarter
Ownership
3.52%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Pentwater Capital Management LP holds $1,105,751,917 across 8 Biotechnology names. RNA ranks #7 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
|
2,870,000 | $329,533,400 | |
| 2 | CNTA |
Centessa Pharmaceuticals plc
|
8,170,000 | $324,512,400 | |
| 3 | APLS |
Apellis Pharmaceuticals, Inc.
|
5,250,000 | $211,207,500 | |
| 4 | FOLD |
AMICUS THERAPEUTICS, INC.
|
14,000,000 | $202,440,000 | |
| 5 | DAWN |
Day One Biopharmaceuticals, Inc.
|
800,000 | $17,152,000 | |
| 6 | GPCR |
Structure Therapeutics Inc.
|
245,000 | $11,809,000 | |
| 7 | RNA |
Atrium Therapeutics, Inc.
This page
|
602,649 | $8,057,417 | |
| 8 | PTCHF |
PureTech Health plc
|
70,000 | $1,040,200 |
All Filings in RNA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,057,417 | 602,649 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||